![]() | |
Names | |
---|---|
IUPAC name (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
| |
| |
Properties | |
C51H69N13O11S2 | |
Molar mass | 1104.31 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
CTAP is an opioid antagonist peptide, which is an analogue of somatostatin. [1] It displays high selectivity for the mu-opioid receptor.
CTAP is described as being a mu-selective opioid antagonist. [2] [3] In other words, when blocking opioid receptors, it is much more selective for the mu-opioid receptors than the other receptors. For example, in Norway rats, it has an IC50 value of 0.0021 µM at mu opioid 1 receptors, [4] but has a value of 5.31 µM at delta opioid 1 receptors, [5] which shows that it is much more selective for mu receptors, as can be seen by the smaller value. Additionally, it is able to cross the blood–brain barrier (BBB). [6]